CONTROL BIONICS LIMITED — Board/Management Information 2023

May 3, 2023

==> picture [177 x 63] intentionally omitted <==

4 May 2023

ASX ANNOUNCEMENT

Appointment of Professor Heard to CBL Board

The Board of Control Bionics Limited welcomes Professor Robert Heard as a new independent non-executive director. Robert is a distinguished medical practitioner and Professor of Neurology who brings a wealth of relevant knowledge and experience to our Board.

Professor Heard replaces Lindsay Phillips, a long-term director of the Company, who is retiring in order to diversify the skill set of the Board and to achieve our goal of having a majority of independent directors.

We take this opportunity to thank Lindsay for his many years of diligent service to the Board and to the Company, and his continued participation as a major shareholder.

This announcement was authorised by CBL Chairman, Roger Hawke.

About Control Bionics:

Control Bionics is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses such as Motor Neurone Disease (MND)/ Amyotrophic Lateral Sclerosis (ALS), Spinal Cord Injury, Traumatic Brain Injury and Cerebral Palsy among others. Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as Electromyography (EMG) signals which are processed on personal computers, smartphones and tablets to generate text, text to speech, email and other computer controlled functions. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics produces the only system to harness three modalities – touch, eye movement and EMG control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

Control Bionics recently extended its offering to mobility with the launch of DROVE – the autonomous wheelchair module. This world first solution allows powered wheelchair users the independence to operate their wheelchairs in the own homes for the first time.

Control Bionics operates in North America, Australia, Singapore and Japan.

Control Bionics Limited Registered Office: Level 5, Suite 5.01, 697 Burke Road, Camberwell, Vic., 3124 T: +61 3 9897 3576 W: www.controlbionics.com

ABN: 45 115 465 462